New compound shows promise as a more effective treatment for schistosomiasis

A newly developed compound is showing promise in animal studies as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms.

Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics’s TN-401?

TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy.

December 14, 2024

Tilray Brands Q4 Cannabis Business Lifts 13%

Tilray Brands Reports Record Financial Results, Achieves 26% Net Revenue Growth Record Fiscal 2024 Gross Profit Reduced Net Convertible Debt by ~$300 Million in Fiscal

July 30, 2024

Patent Filed by Eurofins Scientific SE for Cancer Detection Method with Cell-Free DNA

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData Patent Analytics tracks bibliographic data,

April 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.